What's Going On With BridgeBio Pharma Stock On Monday?

1mon ago, source: Hosted on MSN

During the early trading session, BridgeBio Pharma stock traded higher and reached as high as $36.67. Price Action: BBIO shares are down 7.77% at $32.86 on the last check Monday.

Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments

1mon ago, source: Business Insider

BridgeBio Pharma (BBIO) Company Description: BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 ...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15d ago, source: Business Insider

PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

BridgeBio Pharma, Inc. (BBIO)

2d ago, source: Yahoo Finance

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

BBIO BridgeBio Pharma, Inc.

1mon ago, source: Seeking Alpha

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

BridgeBio Pharma, Inc. (BBIO)

6d ago, source: Yahoo Finance

PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

BridgeBio Pharma Inc BBIO

13d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BridgeBio Pharma Inc (BBIO)

22d ago, source: Investing

Mizuho Securities analyst Salim Syed maintained a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) Inc on Tuesday, setting a price target of $86, which is approximately ...

BridgeBio Pharma Inc (BBIO)

6d ago, source: Investing

On Thursday, Raymond James resumed coverage on BridgeBio Pharma (NASDAQ:BBIO), assigning an Outperform rating and setting a price target of $45.00. The firm's analysis suggests ...